DENVER – Omni Bio Pharmaceutical Inc. (OTCBB: OMBP), a pharmaceutical company focused on commercializing new uses of alpha-1 antitrypsin (AAT) for the treatment of a variety of medical indications and the development of recombinant forms of AAT, announced favorable results for its recombinant molecule, Fc-AAT.
According to data presented on the therapeutic applications of Fc-AAT in gout at the 4th European Workshop on Crystals in Human Diseases in Paris, the molecule has been shown to be effective in suppressing pro-inflammatory responses and was at least 40 times more potent than a clinical grade of plasma-derived AAT.
The data was presented by Leo Joosten of the Radboud University Medical Center in The Netherlands.
“These results are very exciting and suggest that Fc-AAT has high potential for use in the treatment of refractory gout and other inflammatory conditions,” Joosten said.
“We are now considering how best to pursue early clinical trials in patients suffering from this condition.”
“Omni Bio is very pleased to have supported Dr. Joosten’s work, and this first important disclosure of data on our lead Fc-AAT molecule,” said Dr. Bruce Schneider, CEO.
“We will continue to foster the research of Fc-AAT to expand our understanding of its utility in a variety of treatment settings.”
For more information, visit www.omnibiopharma.com.